Tag Archives: RESI

At RESI@TMCx, Make Your Fundraising Budget Count

3 Mar

By Nono Hu, Director of Marketing, LSN

What does it cost to raise capital? In LSN’s experience, one signal that consistently distinguishes a company that is committed to raising capital is that the company has a realistic plan and budget for their fundraising campaign. And when a company has a budget, it’s vital to ensure that they’re getting the most return on investment (ROI) possible from their campaign expenses.

That’s where the Redefining Early Stage Investments (RESI) Conference fits in. As a one-day event with a 1:1 ratio of investors to startup companies, RESI inundates attendees with opportunities to connect. Companies can book up to 16 face-to-face investor meetings in advance of the event; by providing so many opportunities to meet investors in one day, RESI is a high-value event for fundraising CEOs.

RESI Provides a Higher ROI for Cost Conscious CEOs

table
RESI-Houston-2016

Tags: , , ,

RESI@JPM: Biotech Angels Discuss Where and How They Fit into a Fundraise

25 Feb

By Cole Bunn, Research Analyst, LSN

cole-wp

Life science angel investors have long been a fundamental piece of a fundraising campaign, typically providing strategic guidance and capital to entrepreneurs who are right out of the gate. Relaxed crowdfunding provisions and big pharma’s increased involvement in early-stage companies, among other developments, has created new opportunities for angels to find, fund and exit biotech companies. This crucial investor class speaks to the types of deals they like to do, what it’s like to work with an angel investor and how they see the biotech and investment landscapes evolving.

To hear directly from the investors, watch the RESI video recap here:

Tags: , , , , ,

RESI@TMCx: Agenda Announced

11 Feb

By Nono Hu, Director of Marketing, LSN

RESI is returning to TMCx on April 11th, and LSN has scheduled two all-day tracks of panel sessions that illuminate every corner of the life science investment landscape. Panels will feature senior, experienced investors from a diversity of investor types – including family offices, VCs, angel syndicates, major global pharma and medical device firms, and more. These investors will explore new investment trends in their sectors, and will share their knowledge and insights with RESI’s audience of entrepreneurs. If you’d like to join us at RESI@TMCx to hear the latest on life science financing and book one-on-one meetings with investors, you can register here.

Tags: , , ,

RESI@TMCx Take 2: LSN, JLABS and TMCx Team-up Again for Early Stage Investor Event

21 Jan

By Michael Quigley, VP of Market Research, LSN

mike-2

On April 11th, Life Science Nation will be bringing together hundreds of senior level executives from investment firms, corporate strategics, and emerging biotech, medtech and digital health companies to the TMCx accelerator space at the Texas Medical Center in Houston. The recent RESI Conference in San Francisco had nearly 800 registrants and a full partnering floor. The event drew so much interest that registration was shut down a week prior to the event – and we received many regretful notes from those who wished they’d signed up sooner!

In addition to the firepower that LSN brings to the table, TMCx will be showcasing their second class of digital health and medical device technologies which will be announced later this month, and JLABS will be bringing senior executives from Johnson & Johnson and a number of entrepreneurs from the JLABS incubators.

RESI@TMCx will be a venue for entrepreneurs to meet with all 10 categories of investors LSN tracks including Family offices, Corporate Venture Funds, Angel Groups, Venture Philanthropy, Venture Capital and more. The RESI Partnering Forum will allow fundraising executives to identify and book up to 16 meetings with those diverse life science investors who fit their company’s technology sector and stage of development. Through an expansive series of investor panels, RESI @ TMCx will present current topics covering investment mandates and procedures for identifying and qualifying candidates. Additionally, RESI’s workshops will provide more in-depth advice on every aspect of the fundraising process.

 

RESI-Houston-2016_600

eb

Tags: , , , , , , , ,

RESI@JPM Innovation Challenge – Winners Announced

21 Jan

By Nono Hu, Director of Marketing, LSN

Last week, LSN’s Redefining Early Stage Investments (RESI) Conference brought together approximately 350 early stage investors and 300 biotech, medtech and healthcare IT entrepreneurs, our largest crowd to date. The RESI Innovation Challenge received a record number of applicants last fall. The 30 most innovative applicants were hand selected by Life Science Nation’s internal scientific review board and presented their technologies in an exhibition-style format throughout the full-day conference. Here are the top 3 winners!

First Prize Winner: ClearSight

01

ClearSight LLC is commercializing a novel intraocular lens (IOL), the ClearSight IOL, designed to prevent clouding of the lens known as posterior capsular opacification (PCO). PCO is the most frequent surgical complications from cataract surgery, occurring in 25% of patients and costing the U.S. healthcare system $350 million/year. Animal data demonstrates that the ClearSight IOL reduces PCO by 100% in a rabbit model, due to the patent-protected ClearSight IOL design and the addition of a novel microscopic surface texture to prevent cell migration that leads to clouding of the lens. IOLs represent a $1.1 billion U.S. market and $3.7 billion global market.

02

George Ayd, Assistant Vice President, MedMarc; Shravanthi Reddy, COO, ClearSight

 

Second Prize Winner: Eve Medical

03Eve Medical is a Toronto-based medical device company dedicated to improving women’s health. Eve’s core product HerSwab™ makes it easy for women to collect their own samples at home or in clinic to test for common infections that cause cervical cancer, pelvic inflammatory disease and infertility. This saves time, provides privacy and minimizes invasiveness. By reduce barriers to screening, and improving compliance, Eve Medical and HerSwab™ can empower under-served women, improve the reach of existing programs, increase test volumes, and reduce costs for healthcare systems.

04

Michael Quigley, VP of Market Research, LSN; Jessica Ching, CEO, Eve Medical; Dennis Ford, CEO, LSN

 

Third Prize Winner: Briteseed

05The surgeon’s lack of tactile feedback during minimally invasive laparoscopic and robotic surgery leads to difficulty in safely visualizing and manipulating blood vessels, ureters, and bile ducts. Briteseed combats this problem by building smart surgical tools using low-cost optical technology to non-invasively visualize both between and near the jaws of a surgical tool in real time. This combination hardware and software solution is flexible enough to be seamlessly integrated into a spectrum of surgical tools. These smart tools will provide imaging and diagnostic capabilities without interrupting surgical workflow, increasing user adoption. By raising the quality and decreasing overall cost of care, Briteseed provides value to surgeons and the hospital administrations that support them.

06

Michael Quigley, VP of Market Research, LSN; Mayank Vijay, Head of BD and Operations & Co-founder, Briteseed

 

Tags: , , , ,

RESI@TMCx: Innovators Are Invited To Apply

21 Jan

By Lucy Parkinson, Director of Research, LSN

Congratulations to Clearsight, Eve Medical, and Briteseed for their success in the RESI Innovation Challenge last week; at LSN, we hope that the success of these companies in RESI’s virtual fundraising challenge translates into real investor dollars!

If you’re interested in seeing your company’s name up there on the winner’s list, you can now apply to the RESI@TMCx Innovation Challenge for the conference on April 11, 2016. Successful applicants will be provided with a spot in the RESI Exhibitor Hall, and the challenge provides entrepreneurs with a way to engage with RESI’s audience of active life science investors throughout the event. All RESI attendees are provided with “RESI Cash” tokens that they can allocate to the entrepreneurs whose technologies they expect will be most successful. At the end of the day, the capital invested will be tallied up and the top 3 participants will be announced.

This exhibition-style, interaction-focused format was developed by LSN because we’ve found more traditional “pitch contests” to be of poor value for startups. If there are any active life science investors viewing a pitch session (and we’ve found that many investors just aren’t interested in this format), they don’t have a direct way to interact with the pitcher and offer their feedback. RESI therefore focuses on providing startups with the opportunity to meet investors face to face, both through one-on-one meetings and informal networking, and the RESI Innovation Challenge provides entrepreneurs with an eye-catching way to make those in-depth conversations happen.

Previous RESI Innovation Challenge winners include:

Clearsight (Aurora, CO)

Rna Diagnostics (Toronto, ON)

Redox (Madison, WI)

Empiriko (Newton, MA)

ORIG3N (Boston, MA)

Kineta (Seattle, WA)

If you’re developing a cutting-edge biotech or medtech product, apply to the RESI Innovation Challenge to put your technology into the spotlight. We’ll look forward to seeing you at RESI@TMCx.

Tags: , ,

RESI@JPM – The Good News, And The Bad News

7 Jan

By Dennis Ford, Founder & CEO, LSN

dennis-websit

With LSN’s Redefining Early Stage Investments (RESI) conference coming up next Tuesday, I am delighted to announce the good news is RESI seems to have caught fire in the early stage global investor community, with investors making up half of the registered attendees.

The bad news is, when you add that to the fundraising CEOs, RESI Innovation Challenge participants, exhibitors and sponsors, we’ve reached capacity at our venue. We’re therefore unable to take any more registrations.

However, here’s the program guide; we hope that if you didn’t make it to RESI@JPM, you will be able to join us at one of our three events later this year in Houston (April 11th), Toronto (June 23rd), or Boston (September 13th). If you’d like to attend a future RESI event, plan early!

 

Tags: , ,

← Older Entries
Newer Entries →